ATE508635T1 - Virusvektoren und ihre verwendung bei therapeutischen methoden - Google Patents

Virusvektoren und ihre verwendung bei therapeutischen methoden

Info

Publication number
ATE508635T1
ATE508635T1 AT02753865T AT02753865T ATE508635T1 AT E508635 T1 ATE508635 T1 AT E508635T1 AT 02753865 T AT02753865 T AT 02753865T AT 02753865 T AT02753865 T AT 02753865T AT E508635 T1 ATE508635 T1 AT E508635T1
Authority
AT
Austria
Prior art keywords
therapeutic methods
virus vectors
vectors
methods
viral vectors
Prior art date
Application number
AT02753865T
Other languages
English (en)
Inventor
Paul Johnson
Robert Martuza
Samuel Rabkin
Tomoki Todo
Original Assignee
Catherex Inc
Gen Hospital Corp
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23067509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE508635(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Catherex Inc, Gen Hospital Corp, Univ Georgetown filed Critical Catherex Inc
Application granted granted Critical
Publication of ATE508635T1 publication Critical patent/ATE508635T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02753865T 2001-03-27 2002-03-27 Virusvektoren und ihre verwendung bei therapeutischen methoden ATE508635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27906901P 2001-03-27 2001-03-27
PCT/US2002/009512 WO2002076216A1 (en) 2001-03-27 2002-03-27 Viral vectors and their use in therapeutic methods

Publications (1)

Publication Number Publication Date
ATE508635T1 true ATE508635T1 (de) 2011-05-15

Family

ID=23067509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753865T ATE508635T1 (de) 2001-03-27 2002-03-27 Virusvektoren und ihre verwendung bei therapeutischen methoden

Country Status (9)

Country Link
US (6) US7749745B2 (de)
EP (1) EP1381280B1 (de)
JP (2) JP4212897B2 (de)
AT (1) ATE508635T1 (de)
AU (1) AU2002306919B2 (de)
CA (1) CA2441663C (de)
ES (1) ES2366608T3 (de)
FR (1) FR16C0028I2 (de)
WO (1) WO2002076216A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
EP1381280B1 (de) 2001-03-27 2011-05-11 Catherex, Inc. Virusvektoren und ihre verwendung bei therapeutischen methoden
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US7655459B2 (en) * 2004-03-31 2010-02-02 Tomoki Todo Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
WO2005103237A1 (ja) * 2004-03-31 2005-11-03 Tomoki Todo 組換え単純ヘルペスウイルスの作製方法
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP2307033A4 (de) * 2008-05-29 2012-06-13 Gen Hospital Corp Verwendung von onkolytischen herpesviren zur tötung von krebsstammzellen
US9267151B2 (en) * 2008-08-20 2016-02-23 Brainco Biopharma, S.L. STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
WO2011101912A1 (ja) 2010-02-19 2011-08-25 国立大学法人東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
EP2753355B1 (de) 2011-09-08 2018-10-24 New York University Onkolytisches herpes-simplex-virus und therapeutische verwendungen davon
DK3184641T3 (da) 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
CN107580626A (zh) 2014-12-18 2018-01-12 美国安进公司 稳定冷冻病毒制剂
EP3307330B1 (de) 2015-06-15 2021-03-10 New York University Verfahren zur behandlung unter verwendung onkolytischer viren
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
RU2749050C2 (ru) 2016-01-27 2021-06-03 Онкорус, Инк. Онколитические вирусные векторы и их применение
EP3474889A4 (de) 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. Rekombinante cytomegalovirus-vektoren als impfstoffe gegen tuberkulose
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US20200009204A1 (en) 2017-03-15 2020-01-09 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN106974942A (zh) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
EP3658165A4 (de) 2017-07-26 2021-09-01 Oncorus, Inc. Onkolytische virusvektoren und verwendungen davon
CN111164100B (zh) 2017-08-03 2024-03-12 美国安进公司 白介素-21突变蛋白和治疗方法
CN111246883A (zh) 2017-08-07 2020-06-05 美国安进公司 用抗pd-l1抗体和溶瘤病毒治疗三阴性乳癌或结肠直肠癌伴随肝转移
JP7150823B2 (ja) 2017-09-08 2022-10-11 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法
EP3697806A4 (de) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberkulose-antigen-kassetten
EP3731850A4 (de) 2017-12-29 2021-12-01 Oncorus, Inc. Onkolytische virale verabreichung von therapeutischen polypeptiden
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
JP7429046B2 (ja) 2018-03-30 2024-02-07 具紀 藤堂 腫脹発生抑制型腫瘍溶解性ウイルス
EP3653716A1 (de) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replikationskompetente gesteuerte alpha-herpesvirus-virusvektoren und verwendungen davon
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
CN113439123A (zh) 2019-03-05 2021-09-24 安进公司 溶瘤病毒用于治疗癌症的用途
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
US20230147832A1 (en) * 2020-01-22 2023-05-11 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
WO2024038857A1 (ja) * 2022-08-16 2024-02-22 具紀 藤堂 単純ヘルペスウイルスベクターを含む医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659628B1 (fr) * 1990-03-16 1992-09-18 Marin S Communication Dispositif de boite ou d'etui a couvercle mobile.
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5750398A (en) 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
AU6814601A (en) * 2000-06-01 2001-12-11 Sloan Kettering Inst Cancer Use of mutant herpes viruses and anticancer agents in the treatment of cancer
EP1381280B1 (de) * 2001-03-27 2011-05-11 Catherex, Inc. Virusvektoren und ihre verwendung bei therapeutischen methoden

Also Published As

Publication number Publication date
US9555072B2 (en) 2017-01-31
JP2009060907A (ja) 2009-03-26
JP2004528836A (ja) 2004-09-24
US20200345835A1 (en) 2020-11-05
US8871193B2 (en) 2014-10-28
JP4212897B2 (ja) 2009-01-21
WO2002076216A1 (en) 2002-10-03
US10532095B2 (en) 2020-01-14
EP1381280A1 (de) 2004-01-21
FR16C0028I2 (fr) 2018-05-11
US20020187163A1 (en) 2002-12-12
ES2366608T3 (es) 2011-10-21
US20150071965A1 (en) 2015-03-12
US20130280299A1 (en) 2013-10-24
EP1381280A4 (de) 2006-06-14
CA2441663C (en) 2013-01-22
US20170290908A1 (en) 2017-10-12
AU2002306919B2 (en) 2007-11-22
CA2441663A1 (en) 2002-10-03
US7749745B2 (en) 2010-07-06
US20110070262A1 (en) 2011-03-24
FR16C0028I1 (fr) 2016-07-22
US8470577B2 (en) 2013-06-25
EP1381280B1 (de) 2011-05-11

Similar Documents

Publication Publication Date Title
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE486087T1 (de) Fgf-5-bindende und geträgerte peptide
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE526019T1 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ATE411984T1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
EA200400399A1 (ru) Способы лечения легочных заболеваний
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
ATE295727T1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties